Clene Delays ALS NDA Filing to Q4 2026, Targets Mid-2027 FDA Decision

What happened

Clene announced plans to submit the NDA for CNM-Au8 in ALS at the start of Q4 2026, pushing back its previous end-2025 timeline and setting expectations for a potential FDA decision by mid-2027. The delay follows extended FDA interactions, including a Type C meeting in Q3 2025, where the agency's prior skepticism about biomarker and open-label survival data necessitated additional preparation. The company continues to face significant financial strain, with cash around $7.3 million as of Q2 2025, a going-concern warning, and negative free cash flow of roughly $4–7 million per quarter. The withdrawal of Amylyx's Relyvrio in 2024 has reopened the ALS market, but also underscores the high bar for confirmatory efficacy that Clene must meet. Investors await clarity on whether the FDA will accept an accelerated approval filing based on the accumulated evidence, and whether Clene can secure funding to support the filing and subsequent confirmatory trial.

Implication

With the NDA now targeted for Q4 2026 and a decision not until mid-2027, Clene must fund operations for at least another year or more, likely requiring substantial new capital given its current burn rate. The delay suggests that the FDA discussions have not yet yielded a clear path to accelerated approval, and the company may need to strengthen its data package, increasing the risk of a complete response or refusal to file. While the oral nanocrystal platform retains long-term potential and the ALS market has unmet need, the near-term investment case hinges almost entirely on regulatory acceptance and financing. Until the company provides concrete evidence of a viable funding solution and a positive FDA signal, the stock could remain under pressure, with significant downside if the filing is rejected or delayed further. For risk-tolerant investors, any favorable update on FDA alignment or a non-dilutive partnership could trigger a sharp re-rating, but the asymmetric risk currently favors patience.

Thesis delta

The new timeline confirms a material delay from the previous end-2025 NDA target, increasing near-term uncertainty and heightening the already acute financing risk. However, the core investment thesis remains unchanged: CNM-Au8 still holds optionality in ALS, but regulatory acceptance and funding are unresolved. Consequently, the prior WAIT/NEUTRAL judgment is maintained, albeit with greater caution given the extended cash burn period.